Margaret Dugan, the Chief Medical Officer of $SDGR, sold 1,395 shares of the company on 10-16-2025 for an estimated $29,387. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.4% of their shares of this class of stock. Following this trade, they now own 24,574 shares of this class of $SDGR stock.
$SDGR Insider Trading Activity
$SDGR insiders have traded $SDGR stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SDGR stock by insiders over the last 6 months:
- MARGARET DUGAN (Chief Medical Officer) sold 1,395 shares for an estimated $29,387
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SDGR Hedge Fund Activity
We have seen 117 institutional investors add shares of $SDGR stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CADIAN CAPITAL MANAGEMENT, LP added 1,940,952 shares (+175.7%) to their portfolio in Q2 2025, for an estimated $39,051,954
- BLACKROCK, INC. added 1,313,367 shares (+15.5%) to their portfolio in Q2 2025, for an estimated $26,424,944
- FARALLON CAPITAL MANAGEMENT LLC added 1,106,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $22,252,720
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 942,252 shares (-21.6%) from their portfolio in Q2 2025, for an estimated $18,958,110
- UBS GROUP AG added 929,034 shares (+226.1%) to their portfolio in Q2 2025, for an estimated $18,692,164
- TOCQUEVILLE ASSET MANAGEMENT L.P. removed 732,600 shares (-65.2%) from their portfolio in Q2 2025, for an estimated $14,739,912
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 598,551 shares (-28.6%) from their portfolio in Q2 2025, for an estimated $12,042,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SDGR Analyst Ratings
Wall Street analysts have issued reports on $SDGR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 10/08/2025
- Barclays issued a "Overweight" rating on 08/14/2025
To track analyst ratings and price targets for $SDGR, check out Quiver Quantitative's $SDGR forecast page.
$SDGR Price Targets
Multiple analysts have issued price targets for $SDGR recently. We have seen 6 analysts offer price targets for $SDGR in the last 6 months, with a median target of $22.5.
Here are some recent targets:
- Scott Schoenhaus from Keybanc set a target price of $28.0 on 10/08/2025
- Andrea Newkirk from Goldman Sachs set a target price of $19.0 on 09/30/2025
- Vikram Malhorta from Morgan Stanley set a target price of $19.0 on 08/18/2025
- David Lebowitz from Citigroup set a target price of $20.0 on 08/15/2025
- Peter Lawson from Barclays set a target price of $25.0 on 08/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
